23rd Jun 2016 06:16
LONDON (Alliance News) - FTSE 100-listed drugmaker AstraZeneca PLC on Thursday said the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention in the US has made a negative interim recommendation on the use of the UK's group's FluMist treatment for the 2016-17 influenza season.
The updated guidance from the ACIP states the vaccine should not be used in any setting, based on CDC vaccine effectiveness data from the last three influenza seasons in the US. This indicated AstraZeneca's FluMist Quadrivalent did not demonstrate any statistically-significant effectiveness in children aged between two and 17.
AstraZeneca said the data from the CDC contrast with its own studies and those from health authorities in other countries, which showed a 46% to 58% effectiveness of the vaccine against circulating influenza strains.
AstraZeneca said distribution and use of the vaccine is progressing as planned in other countries.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca